Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Franck Chenu"'
Publikováno v:
Journal of Psychopharmacology. 28:162-167
Melatonin has been widely used for the management of insomnia, but is devoid of antidepressant effect in the clinic. In contrast, agomelatine which is a potent melatonin receptor agonist is an effective antidepressant. It is, however, a potent seroto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dcae1fcce71c7a99e0631b96377c62c
https://doi.org/10.1177/0269881113510071
https://doi.org/10.1177/0269881113510071
Publikováno v:
The International Journal of Neuropsychopharmacology. 14:211-223
Triple reuptake inhibitors represent a potential new class of antidepressant drugs that block norepinephrine (NE), dopamine (DA) and serotonin [5-hydroxytryptamine (5-HT)] transporters. The present in-vivo electrophysiological study was undertaken to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc175416f1b2f0753bdd4c5b382bb65a
https://doi.org/10.1017/s1461145710000076
https://doi.org/10.1017/s1461145710000076
Publikováno v:
Behavioural Brain Research. 205:421-425
Topiramate and phenytoin possess mood stabilizing properties. The mechanism of action of anticonvulsants used in the treatment of bipolar depression is complex and still not completely elucidated. Na+ channels are present at distinct sites in neurons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2def244218616f0a825ec442b512d107
https://doi.org/10.1016/j.bbr.2009.07.030
https://doi.org/10.1016/j.bbr.2009.07.030
Publikováno v:
Current Drug Targets. 10:1052-1060
Antidepressant drugs modify in different ways the activity of neurons, by increasing monoamines levels and by modulating ion channels. Sodium channels are molecular targets for antiepileptic drugs, which can also be mood stabilizers (i.e. lamotrigine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196c29a6916af1e77bf95f0933087e3a
https://doi.org/10.2174/138945009789735138
https://doi.org/10.2174/138945009789735138
Publikováno v:
Psychopharmacology. 206:97-107
A deficiency in brain monoamine systems (serotonin, dopamine, and/or norepinephrine) have long been hypothesized for the pathogenesis of depression. Drugs enhancing neurotransmission of those monoamines have been proven to have antidepressant effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1df974007a0deb1121d75b1e2001600e
https://doi.org/10.1007/s00213-009-1583-7
https://doi.org/10.1007/s00213-009-1583-7
Autor:
Alain M. Gardier, Franck Chenu, Christelle Repérant, Michel Bourin, Miklós Tóth, Jean-Philippe Guilloux, Bruno P. Guiard, Denis J. David
Publikováno v:
Neuropsychopharmacology. 31:2162-2172
Selective serotonin reuptake inhibitors like paroxetine (Prx) often requires 4-6 weeks to achieve clinical benefits in depressed patients. Pindolol shortens this delay and it has been suggested that this effect is mediated by somatodendritic 5-hydrox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d737f311575edde18d8b8c58a8a80cf
https://doi.org/10.1038/sj.npp.1301019
https://doi.org/10.1038/sj.npp.1301019
Publikováno v:
Journal of Neuroscience Methods. 150:111-115
The aim of this work is to define neurotoxins doses to have efficient and specific depletion of noradrenaline (NA), serotonin (5-HT) neurotransmission in cortex, striatum, hippocampus and hypothalamus of Swiss mice after intraperitoneal administratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5e86687ecff2354b3a1728d12166fa5
https://doi.org/10.1016/j.jneumeth.2005.06.008
https://doi.org/10.1016/j.jneumeth.2005.06.008
Publikováno v:
Drug Development Research. 65:141-146
It is generally accepted that about two thirds of patients treated for depression respond only after several weeks (2 to 8 weeks) whilst a third do not respond at all. A depressed patient's response to a treatment is defined by at least 50% reduction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a775befecb22090d2ac31a3ac9ae113b
https://doi.org/10.1002/ddr.20017
https://doi.org/10.1002/ddr.20017
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 38(2)
Agomelatine is a melatonergic MT1/MT2 agonist and a serotonin (5-HT) 5-HT(2C) antagonist. The effects of 2-day and 14-day administration of agomelatine were investigated on the activity of ventral tegmental area (VTA) dopamine (DA), locus coeruleus (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5c6b1cee645a33297cd4506244b7e12
https://pubmed.ncbi.nlm.nih.gov/22871919
https://pubmed.ncbi.nlm.nih.gov/22871919
Publikováno v:
The international journal of neuropsychopharmacology. 15(4)
Increasing attention is now focused on reduced dopaminergic neurotransmission in the forebrain as participating in depression. The present paper assessed whether effective antidepressant (AD) treatments might counteract, or compensate for, such a cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e32bf967264f8909142fad7c74fb583
https://pubmed.ncbi.nlm.nih.gov/20482941
https://pubmed.ncbi.nlm.nih.gov/20482941